title: Anti-hyperglycemic activity of chromium(III) malate complex in alloxan-induced diabetic rats.
abstract: The synthesis, characterization, anti-hyperglycemic activity, oxidative DNA damage capacity, and acute toxicity of chromium(III) malate complex [Cr2(LMA)3] were described. [Cr2(LMA)3] was synthesized in a single-step reaction by chelating chromium(III) with L-malic acid in aqueous solution. Based on elemental analysis, thermodynamic analysis, and spectroscopy studies, the molecular formula of [Cr2(LMA)3] was inferred as Cr2(C4H4O5)3·5H2O. Daily treatment with 2.85-17.10 mg/kg body mass of [Cr2(LMA)3] in alloxan-induced diabetic rats for 2 weeks indicated that low-molecular-weight organic chromium complex [Cr2(LMA)3] had better bioavailability and more beneficial influences on the improvement of controlling blood glucose, serum lipid, and liver glycogen levels compared with CrCl3·6H2O. [Cr2(LMA)3] did not cause oxidative DNA damage under physiologically relevant conditions. Acute toxicity studies revealed no-measurable toxicity of the [Cr2(LMA)3]. Collectively, these results suggest that [Cr2(LMA)3] may represent a novel, proper chromium supplement with potential therapeutic value to control blood glucose and serum lipid in diabetes.
authors.affiliation: School of Chemistry and Chemical Engineering, Jiangsu University, 301 Xuefu Rd., 212013, Zhenjiang, Jiangsu, China.
authors.forename: Xiang-Yang
authors.initials: XY
authors.lastname: Wu
authors.forename: Fang
authors.initials: F
authors.lastname: Li
authors.forename: Wei-Dong
authors.initials: WD
authors.lastname: Xu
authors.forename: Jiang-Li
authors.initials: JL
authors.lastname: Zhao
authors.forename: Ting
authors.initials: T
authors.lastname: Zhao
authors.forename: Ling-Hong
authors.initials: LH
authors.lastname: Liang
authors.forename: Liu-Qing
authors.initials: LQ
authors.lastname: Yang
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000187:drug effects; D002784:Cholesterol / Q000378:metabolism; D017608:Chromium Compounds / Q000627:therapeutic use*; D004249:DNA Damage / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008112:Liver Glycogen / Q000378:metabolism; D008297:Male; D051381:Rats; D014280:Triglycerides / Q000378:metabolism
chemical_list: D001786:Blood Glucose; D017608:Chromium Compounds; D007004:Hypoglycemic Agents; D008112:Liver Glycogen; D014280:Triglycerides; D002784:Cholesterol